Abstract
Aromatase is the enzyme responsible for the conversion of androgens to estrogens and represents the main source of local estrogens in post-menopausal breast cancer tissue. Nonsteroidal aromatase inhibitors (NSAIs) are able to reduce growth-stimulatory effects of estrogens in hormone-dependent breast cancer, and third generation NSAIs are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic advanced breast cancer. Nevertheless, some issues in this area still need to be addressed and research efforts are aimed both at identifying new molecules of therapeutic interest and at exploring different options for the modulation of this enzyme. In this review, an update of the latest developments in the field of NSAIs is presented, to provide a broad view on the recent progress in this area. Beside classical structure-activity relationships studies and development of natural product derivatives, rational approaches for both ligand- and structure-based design are described. Moreover, novel strategies for the development of multitarget-directed molecules are also presented. Finally, some possible future developments in this research area are briefly considered.
Keywords: Drug discovery, breast cancer, antiestrogen, CYP-450, structure-activity relationships
Current Topics in Medicinal Chemistry
Title: From Nonsteroidal Aromatase Inhibitors to Multifunctional Drug Candidates: Classic and Innovative Strategies for the Treatment of Breast Cancer
Volume: 8 Issue: 10
Author(s): Silvia Gobbi, Andrea Cavalli, Alessandra Bisi and Maurizio Recanatini
Affiliation:
Keywords: Drug discovery, breast cancer, antiestrogen, CYP-450, structure-activity relationships
Abstract: Aromatase is the enzyme responsible for the conversion of androgens to estrogens and represents the main source of local estrogens in post-menopausal breast cancer tissue. Nonsteroidal aromatase inhibitors (NSAIs) are able to reduce growth-stimulatory effects of estrogens in hormone-dependent breast cancer, and third generation NSAIs are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic advanced breast cancer. Nevertheless, some issues in this area still need to be addressed and research efforts are aimed both at identifying new molecules of therapeutic interest and at exploring different options for the modulation of this enzyme. In this review, an update of the latest developments in the field of NSAIs is presented, to provide a broad view on the recent progress in this area. Beside classical structure-activity relationships studies and development of natural product derivatives, rational approaches for both ligand- and structure-based design are described. Moreover, novel strategies for the development of multitarget-directed molecules are also presented. Finally, some possible future developments in this research area are briefly considered.
Export Options
About this article
Cite this article as:
Gobbi Silvia, Cavalli Andrea, Bisi Alessandra and Recanatini Maurizio, From Nonsteroidal Aromatase Inhibitors to Multifunctional Drug Candidates: Classic and Innovative Strategies for the Treatment of Breast Cancer, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911590
DOI https://dx.doi.org/10.2174/156802608784911590 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Isolation of a Phytase with Distinctive Characteristics from an Edible Mushroom, Pleurotus eryngii
Protein & Peptide Letters A Review of Mechanisms of Circumvention and Modulation of Chemotherapeutic Drug Resistance
Current Cancer Drug Targets Breast Cancer in the Personal Genomics Era
Current Genomics Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Current Pharmaceutical Design The V-ATPase as a Target for Antifungal Drugs
Current Protein & Peptide Science E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Computational Approaches for Translational Oncology: Concepts and Patents
Recent Patents on Anti-Cancer Drug Discovery Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer
Current Cancer Drug Targets Development and Characterization of Solid Dispersion System for Enhancing the Solubility and Dissolution Rate of Dietary Capsaicin
Current Drug Therapy Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews Use of the Semiconductor Nanotechnologies “Quantum Dots” for in vivo Cancer Imaging
Recent Patents on Anti-Cancer Drug Discovery Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications
Current Topics in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets